Regenxbio RGNX
NASDAQ RGNX
$7.52 +0.07 (+0.94%)
As of: Sep 30, 2026 · 3:59 PM EDT

Regenxbio (RGNX) Debt Ratio (2014)

Updated

Regenxbio's (RGNX) Debt Ratio was 0.69 for Q4 2014.

Analysis

Regenxbio (RGNX) Debt Ratio (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 0.24
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 0.52
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 0.42
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 0.31
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 0.00
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 0.60
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Regenxbio 403.52 Mn -529.57 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 0.69
API Access

Regenxbio Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=RGNX&period=max&api_key=YOUR_API_KEY